CC10 reduces inflammation in meconium aspiration syndrome in newborn piglets

Robert M. Angert, Aprile L. Pilon, Darrin Chester, Jonathan M. Davis

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Complications from meconium aspiration syndrome (MAS) remain significant despite a variety of therapeutic interventions. Clara cell protein (CC10) is a novel anti-inflammatory agent that can also inhibit phospholipase A2 (PLA2) (an important component of meconium). The present study examined whether administration of recombinant human CC10 (rhCC10) would reduce inflammation and improve lung function in a piglet model of MAS. Following meconium instillation, piglets exhibited significant physiologic dysfunction that improved significantly after surfactant administration. Analysis of tracheal aspirates revealed significant increases in both tumor necrosis factor (TNF) α and interleukin (IL)-8 after meconium instillation. rhCC10-treated animals had significantly lower TNF-α levels at 24 h (561 ± 321 versus 1357 ± 675 pg/mL, p < 0.05) compared with saline controls. There were no differences between rhCC10-treated and untreated groups with respect to other measured physiologic variables or inflammatory markers, including secretory PLA2 activity. Histologic analyses revealed marked inflammatory infiltrates and thickened alveolar walls, but no significant differences among rhCC10 and control animals. Newborn piglets with MAS have significant physiologic dysfunction, marked inflammatory changes and histologic abnormalities, which was partially counteracted by a single dose of exogenous surfactant and rhCC10.

Original languageEnglish (US)
Pages (from-to)684-688
Number of pages5
JournalPediatric Research
Volume62
Issue number6
DOIs
StatePublished - Dec 2007
Externally publishedYes

Fingerprint

Meconium Aspiration Syndrome
Meconium
Inflammation
Surface-Active Agents
Tumor Necrosis Factor-alpha
Secretory Phospholipase A2
Phospholipases A2
Interleukin-8
Pneumonia
Anti-Inflammatory Agents
Proteins

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

CC10 reduces inflammation in meconium aspiration syndrome in newborn piglets. / Angert, Robert M.; Pilon, Aprile L.; Chester, Darrin; Davis, Jonathan M.

In: Pediatric Research, Vol. 62, No. 6, 12.2007, p. 684-688.

Research output: Contribution to journalArticle

Angert, Robert M. ; Pilon, Aprile L. ; Chester, Darrin ; Davis, Jonathan M. / CC10 reduces inflammation in meconium aspiration syndrome in newborn piglets. In: Pediatric Research. 2007 ; Vol. 62, No. 6. pp. 684-688.
@article{99016b18884347039391a7be390b8c8d,
title = "CC10 reduces inflammation in meconium aspiration syndrome in newborn piglets",
abstract = "Complications from meconium aspiration syndrome (MAS) remain significant despite a variety of therapeutic interventions. Clara cell protein (CC10) is a novel anti-inflammatory agent that can also inhibit phospholipase A2 (PLA2) (an important component of meconium). The present study examined whether administration of recombinant human CC10 (rhCC10) would reduce inflammation and improve lung function in a piglet model of MAS. Following meconium instillation, piglets exhibited significant physiologic dysfunction that improved significantly after surfactant administration. Analysis of tracheal aspirates revealed significant increases in both tumor necrosis factor (TNF) α and interleukin (IL)-8 after meconium instillation. rhCC10-treated animals had significantly lower TNF-α levels at 24 h (561 ± 321 versus 1357 ± 675 pg/mL, p < 0.05) compared with saline controls. There were no differences between rhCC10-treated and untreated groups with respect to other measured physiologic variables or inflammatory markers, including secretory PLA2 activity. Histologic analyses revealed marked inflammatory infiltrates and thickened alveolar walls, but no significant differences among rhCC10 and control animals. Newborn piglets with MAS have significant physiologic dysfunction, marked inflammatory changes and histologic abnormalities, which was partially counteracted by a single dose of exogenous surfactant and rhCC10.",
author = "Angert, {Robert M.} and Pilon, {Aprile L.} and Darrin Chester and Davis, {Jonathan M.}",
year = "2007",
month = "12",
doi = "10.1203/PDR.0b013e31815a5632",
language = "English (US)",
volume = "62",
pages = "684--688",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - CC10 reduces inflammation in meconium aspiration syndrome in newborn piglets

AU - Angert, Robert M.

AU - Pilon, Aprile L.

AU - Chester, Darrin

AU - Davis, Jonathan M.

PY - 2007/12

Y1 - 2007/12

N2 - Complications from meconium aspiration syndrome (MAS) remain significant despite a variety of therapeutic interventions. Clara cell protein (CC10) is a novel anti-inflammatory agent that can also inhibit phospholipase A2 (PLA2) (an important component of meconium). The present study examined whether administration of recombinant human CC10 (rhCC10) would reduce inflammation and improve lung function in a piglet model of MAS. Following meconium instillation, piglets exhibited significant physiologic dysfunction that improved significantly after surfactant administration. Analysis of tracheal aspirates revealed significant increases in both tumor necrosis factor (TNF) α and interleukin (IL)-8 after meconium instillation. rhCC10-treated animals had significantly lower TNF-α levels at 24 h (561 ± 321 versus 1357 ± 675 pg/mL, p < 0.05) compared with saline controls. There were no differences between rhCC10-treated and untreated groups with respect to other measured physiologic variables or inflammatory markers, including secretory PLA2 activity. Histologic analyses revealed marked inflammatory infiltrates and thickened alveolar walls, but no significant differences among rhCC10 and control animals. Newborn piglets with MAS have significant physiologic dysfunction, marked inflammatory changes and histologic abnormalities, which was partially counteracted by a single dose of exogenous surfactant and rhCC10.

AB - Complications from meconium aspiration syndrome (MAS) remain significant despite a variety of therapeutic interventions. Clara cell protein (CC10) is a novel anti-inflammatory agent that can also inhibit phospholipase A2 (PLA2) (an important component of meconium). The present study examined whether administration of recombinant human CC10 (rhCC10) would reduce inflammation and improve lung function in a piglet model of MAS. Following meconium instillation, piglets exhibited significant physiologic dysfunction that improved significantly after surfactant administration. Analysis of tracheal aspirates revealed significant increases in both tumor necrosis factor (TNF) α and interleukin (IL)-8 after meconium instillation. rhCC10-treated animals had significantly lower TNF-α levels at 24 h (561 ± 321 versus 1357 ± 675 pg/mL, p < 0.05) compared with saline controls. There were no differences between rhCC10-treated and untreated groups with respect to other measured physiologic variables or inflammatory markers, including secretory PLA2 activity. Histologic analyses revealed marked inflammatory infiltrates and thickened alveolar walls, but no significant differences among rhCC10 and control animals. Newborn piglets with MAS have significant physiologic dysfunction, marked inflammatory changes and histologic abnormalities, which was partially counteracted by a single dose of exogenous surfactant and rhCC10.

UR - http://www.scopus.com/inward/record.url?scp=36348990750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36348990750&partnerID=8YFLogxK

U2 - 10.1203/PDR.0b013e31815a5632

DO - 10.1203/PDR.0b013e31815a5632

M3 - Article

C2 - 17957145

AN - SCOPUS:36348990750

VL - 62

SP - 684

EP - 688

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

IS - 6

ER -